Matthew Wieduwilt, MD, PhD, of the OU Stephenson Cancer Center, Oklahoma City, OK, gives an overview of strategies to optimize conventional chemotherapy for the treatment of patients with acute lymphoblastic leukemia (ALL). Dr Wieduwilt comments on data from the CALGB 10304 study (NCT00558519) which investigated the feasibility of using a pediatric treatment regimen in adolescents and young adults with ALL. Dr Wieduwilt also talks on how novel targeted therapies, such as the monoclonal antibody inotuzumab ozogamicin, blinatumomab or venetoclax, may impact the use of conventional chemotherapy in the future. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Matthew Wieduwilt, MD, PhD has participates in advisory boards with Gilead/Kite and Servier; and is a stock holder of Reata.